Navigation Links
Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension
Date:12/10/2010

SAN DIEGO, Dec. 10, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension, or PAH.

"An orally bioavailable prostacyclin receptor agonist could improve the standard of care for patients with PAH, a life-threatening disorder," said William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "APD811 is a non-prostanoid compound; in preclinical studies, the oral uptake, half life and efficacy characteristics suggest that it could offer improved administration over current prostacyclin receptor therapies."

This randomized, double-blind and placebo-controlled Phase 1 trial is planned to enroll up to 72 healthy adult volunteers and will evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD811.

"While our primary focus is on achieving FDA approval of lorcaserin for weight management, we see value in advancing our promising earlier-stage compounds that may also address underserved medical needs," said Jack Lief, Arena's President and Chief Executive Officer. "With a measured investment, we aim to establish a favorable pharmacokinetic and preliminary safety profile for APD811 in this trial."

About Pulmonary Arterial Hypertension (PAH)PAH is a progressive, life-threatening disorder characterized by increased pressure in the arteries that carry blood from the heart to the lungs. The increased pressure puts a strain on the heart, which can lead to limited physical activity and a reduced life expectancy. Over time, the heart muscle weakens and can no longer pump blood efficiently. If PAH is not treated, the heart will eventually fail. Data from the National Institute
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces Third Quarter 2010 Financial Results and Reviews Recent Developments
2. Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes
3. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
4. Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
5. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
6. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
7. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
8. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
9. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
11. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data ... devices market. The report provides value, ... volume (in units) within market categories ... Sigmoidoscopes, Esophagoscopes & Gastroscopes, Duodenoscopes, Laparoscopes, ...
(Date:9/19/2014)... Sept. 19, 2014  For Cloud Pharmaceuticals, Inc., ... and development, partnering is an integral part of ... design new drugs and identify early stage, preclinical, ... further their development. The company also partners with ... this business model, Cloud Pharmaceuticals will be participating ...
(Date:9/19/2014)... Mich. , Sept. 19, 2014  Diplomat, the ... of David Dreyer to the Board of ... independent director and will also serve as chair of ... almost 30 years of accounting, financial, compliance and operating ... Mr. Dreyer has served as chief financial officer, chief ...
Breaking Medicine Technology:United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2David Dreyer Appointed to Diplomat Board of Directors 2
... 2011 Virtual Radiologic (vRad), a technology-enabled national ... PACS alternative solution, has been selected by Abbeville ... in upstate South Carolina. AAMC ... to traditional on-premise PACS that was developed by ...
... 2011 Reportlinker.com announces that a new ... catalogue: Medical Devices - ... This package contains 15 medical ... countries: Azerbaijan, China, India, Indonesia, Iran, Japan, ...
Cached Medicine Technology:vRad Selected by Abbeville Area Medical Center for PACS Replacement 2vRad Selected by Abbeville Area Medical Center for PACS Replacement 3Medical Devices - Asia 2
(Date:9/19/2014)... On September 16, Camino Public Relations ... and Top Places to Work in PR Awards Luncheon ... received honorable mentions in two categories for “Multicultural Campaign” ... elevating Latina voices in the media. , "We're honored ... part of its efforts to improve the national conversation ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Hastings and Hastings, ... years in the industry, announces a record number of visitors ... a wide variety of serious injury cases as well as ... with dog bite related accident cases and others. Having served ... Hastings has stood the test of time when it comes ...
(Date:9/19/2014)... 19, 2014 Visiting Nurse Association (VNA) ... health care, hospice and palliative care and community-based care, ... Opening Bell yesterday at the New York Stock Exchange. ... and social entrepreneur to care for immigrant families suffering ... always worked to meet the urgent healthcare needs of ...
(Date:9/19/2014)... York, New York (PRWEB) September 19, 2014 ... in a transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) ... state court next month, Bernstein Liebhard LLP reports. ... in Dallas District Court, the company asserts that claims ... the Texas Civil Practice and Remedies Code, a section ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- Your brain structure could help ... new study suggests. Researchers at Yale University found those ... as the parietal cortex may be more likely to engage ... area. , , The study, funded by the U.S. National ... and women living in the Northeast. The researchers sought to ...
Breaking Medicine News(10 mins):Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Brain Structure Might Help Predict Risky Behavior 2
... Anchorage-independent Assay for Screening Compounds for Inhibition of ... Inc. announced today that it has received U.S. ... Cancer BioChip System (CBCS) for the identification and ... in vitro setting with great clinical ...
... combination therapy of daily consensus interferon (CIFN) and ribavirin is ... do not respond to standard therapy. The treatment works particularly ... to a new study in the June issue of ... on behalf of the American Association for the Study of ...
... people are pulling back on cosmetic procedures during the recession, ... laser vein removal . Unfortunately, most people who ... realize that beautiful, healthy legs are within their budget since ... varicose veins removed promptly, individuals are at ...
... Teel as President of Premier Anesthesia, a national anesthesia management company ... ... May 28, 2009 -- Jackson Healthcare announces the appointment ... management company based in Atlanta, Georgia., , , , ,"Having been ...
... took a major step forward to save lives and ... $1 per pack surcharge into law. Additionally, the governor ... smoking cessation services for Floridians, including monies for the ... fourth lowest in the nation. When the surcharge goes ...
... the Sisters of Charity Health System continues its strategic ... commitment to growing its physician collaboration strategies. Key to ... Jr. in the new position of senior vice president ... position May 28. "As we move through this transition ...
Cached Medicine News:Health News:Falcon Genomics Awarded Patent for Innovative Cancer Test 2Health News:New treatment option for patients with chronic hepatitis C 2Health News:Get Sexy Summer Legs From Renaissance Laser and Vein Institute (laserandveinclinic.com) Courtesy of Your Health Insurance 2Health News:Kerry Teel Named President of Premier Anesthesia 2Health News:Kerry Teel Named President of Premier Anesthesia 3Health News:Florida's $1 Cigarette Tax Increase a Big Win for Public Health 2Health News:Florida's $1 Cigarette Tax Increase a Big Win for Public Health 3Health News:Sisters of Charity Health System Appoints Orlando L. Alvarez Jr. to Head Physician Strategy and Business Development 2Health News:Sisters of Charity Health System Appoints Orlando L. Alvarez Jr. to Head Physician Strategy and Business Development 3
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Detection of Lupus Anticoagulants. Freeze-dried hexagonal phase phos-phatidylethanolamine; normal plasma with heparin inhibitor; PTT-LS reagent of cephalin and particulate siliceous activator;all fre...
... Protein C Activity by STA© ... of Protein C; highly purified ... venom for specific activation of ... activator selected specially for protein ...
Immuno-turbidimetric Assay for Protein S Antigen. Suspension of microlatex particles coated with specific antibodies....
Medicine Products: